A 24-hour perioperative case study on argatroban use for left ventricle assist device insertion during cardiopulmonary bypass and veno-arterial extracorporeal membrane oxygenation

Abstract

A 44-year-old male with ongoing chest pain and left ventricular ejection fraction <20% was transferred from a peripheral hospital with intra-aortic balloon pump placement following a non-ST-elevation myocardial infarction (STEMI). The patient underwent emergent multi-vessel coronary artery bypass grafting requiring veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) on post-operative day (POD)#9 secondary to cardiogenic shock with biventricular failure. Due to clot formation, an oxygenator change-out was necessary shortly after initiation. Following a positive heparin-induced thrombocytopenia (HIT) assay, a total circuit exchange was required to eliminate all heparin coating and argatroban was deemed the anticoagulant of choice due to acute kidney injury. On POD#24, the decision was made to implant a left ventricle assist device (LVAD) as a bridge to heart transplantation. There was difficulty achieving an activated clotting time (ACT) >400 s: multiple argatroban bolus doses were required, along with accelerated up-titration of infusion dosing. Despite maintaining an ACT >484 s, clot formation was observed in the cardiotomy reservoir prior to separation. Subsequently, the patient developed severe disseminated intravascular coagulopathy, with both intra-cardiac and intravascular thrombi, requiring massive transfusion and continuous cell saving due to severe hemorrhage post cardiopulmonary bypass (CPB). The patient received a total of 105 units of plasma, 74 units of packed red cells, 19 units of platelets, 13 bottles of 5% albumin, 6 units of cryoprecipitate and 2 doses of factor VIIa intraoperatively over the course of 24 hours. A total of 19.7 L of washed red blood cells were returned to the patient from the cell saver. With the LVAD in place, the patient developed transfusion-related acute lung injury and acute respiratory distress syndrome with right ventricular dysfunction requiring VA ECMO once again. On POD#30, ECMO was discontinued and the patient was discharged from the intensive care unit (ICU) on POD 66. After a very complex post-operative stay with numerous surgeries and extensive rehabilitation, the patient was discharged home with the LVAD on POD#112.

Keywords

argatroban LVAD ECMO CPB dosing

Get full access to this article

View all access options for this article.

References

Smith

Stroud

Damiani

et al . Use of Argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy. Eur J Cardiothorac Surg 2008; 34: 1113–1114.

Genzen

Fareed

Hoppensteadt

et al . Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion 2010; 50: 801–807.

Follis

Filippone

Montalbana

et al . Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg 2010; 10: 592–596.

Edwards

Hamby

Worrall

Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003; 75: 1622–1624.

Tanigawa

Yamada

Matsumoto

et al . Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation. J Anesth 2013; 27: 951–955.

Kurup

Transue

et al . Cardiac surgery in a patient with heparin-induced thrombocytopenia-cautions with use of the direct thrombin inhibitor, argatroban. Connecticut Medicine 2006; 70: 245–250.

Agarwal

Ullom

Al-Baghdadi

et al . Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol 2012; 28: 106–110.

Phillips

Khoury

Ashton

et al . The dosing and monitoring of argatroban for heparin induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anesth Intensive Care 2014; 42: 97–98.

Beiderlinden

Treschan

Gorlinger

et al . Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007; 31: 461–465.

10.

Guy

Kithen

Maclean

Van Veen

JJ.

Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. Int J Lab Hematol 2015; 37: 834–843.

11.

Bouraghda

Gillois

Albaladejo

Alternatives to heparin and protamine anticoagulation for cardiopulmonary bypass in cardiac surgery. Can J Anesth 2015; 62: 518–528.

12.

Koster

Dyke

Aldea

et al . Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83: 572–577.

13.

Dyke

Smedira

Koster

et al . A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131: 533–539.